The Sinusitis Script Nobody Talks About: Evaluating Azithromycin's Off-Label Role in Chronic Rhinosinusitis

A Familiar Drug, an Unfamiliar Indication

For most US clinicians, azithromycin occupies a well-worn prescribing niche: community-acquired pneumonia, atypical pathogens, sexually transmitted infections, and the perennial — if increasingly scrutinized — Z-pack for upper respiratory complaints. What receives considerably less attention is the drug's expanding off-label footprint in chronic rhinosinusitis (CRS), a condition affecting an estimated 28 to 30 million American adults annually and generating billions of dollars in direct healthcare costs.

CRS is not a simple infectious process. It is a multifactorial inflammatory disease of the sinonasal mucosa, and that distinction matters enormously when evaluating azithromycin's role. The growing interest in this antibiotic for CRS has little to do with killing bacteria and everything to do with modulating the immune response — a pharmacological dimension that standard antibiotic stewardship conversations rarely address.

Why Immunomodulation, Not Antimicrobial Activity, Is the Real Argument

Azithromycin belongs to the macrolide class, and macrolides as a group have long been recognized for biological effects that extend well beyond pathogen eradication. In the context of CRS, the relevant mechanisms include suppression of pro-inflammatory cytokines such as interleukin-8 and tumor necrosis factor-alpha, impairment of neutrophil recruitment to inflamed mucosa, inhibition of mucus hypersecretion, and interference with bacterial biofilm formation — particularly biofilms associated with Pseudomonas aeruginosa and Staphylococcus aureus.

This immunomodulatory profile is what originally attracted attention in diffuse panbronchiolitis, a rare obstructive airway disease common in East Asian populations where low-dose long-term macrolide therapy demonstrated dramatic clinical benefit. Researchers and clinicians began asking whether similar mechanisms might offer relief in CRS, particularly the non-eosinophilic, neutrophil-dominant subtype that tends to respond poorly to corticosteroids.

The distinction between CRS subtypes is clinically meaningful. CRS with nasal polyps (CRSwNP) is generally driven by a type 2 eosinophilic inflammatory response and tends to respond to intranasal corticosteroids and, more recently, biologic agents. CRS without nasal polyps (CRSsNP), by contrast, is often characterized by neutrophilic inflammation, and it is in this population that macrolide immunomodulation appears most mechanistically plausible.

What the Clinical Evidence Actually Demonstrates

The honest answer is that the evidence base is promising but not yet definitive, and clinicians should approach it accordingly.

Several randomized controlled trials have examined low-dose, long-duration azithromycin regimens in CRS — typically 250 mg three times weekly or 500 mg once weekly for 12 weeks. A frequently cited trial by Wallwork and colleagues published in Laryngoscope demonstrated statistically significant improvements in sinonasal symptom scores and mucociliary clearance in CRS patients without nasal polyps, with the most pronounced benefit in patients with normal baseline serum IgE — a surrogate marker for non-eosinophilic disease.

Additional smaller trials and retrospective series have reported reductions in nasal discharge, postnasal drip, and facial pressure, along with improved endoscopic scores. Meta-analyses aggregating this data have generally concluded that macrolide therapy offers modest but meaningful benefit in CRS without nasal polyps, while results in CRSwNP have been inconsistent.

However, the aggregate trial quality has limitations. Sample sizes are often small, outcome measures lack standardization across studies, follow-up periods are short, and most trials were conducted outside the United States — introducing questions about population generalizability, baseline microbiome differences, and local resistance patterns. The American Academy of Otolaryngology–Head and Neck Surgery Foundation guidelines acknowledge macrolide therapy as a treatment option for CRS, but note that evidence quality remains moderate at best.

The Stewardship Blind Spot

Here is where this indication creates a genuine tension for antimicrobial stewardship programs. Azithromycin used at sub-antimicrobial doses for immunomodulatory purposes still exerts selective pressure on commensal and pathogenic bacteria. Macrolide resistance in Streptococcus pneumoniae and Mycoplasma pneumoniae has been rising across the United States, and prolonged low-dose macrolide exposure — even when the therapeutic intent is not bactericidal — contributes to this trajectory.

Because this use pattern does not fit neatly into traditional stewardship categories (it is not empiric therapy, not treatment of a confirmed infection, and not prophylaxis in the conventional sense), it often escapes stewardship review entirely. Prescriptions written in ENT offices or primary care settings for a 12-week course of azithromycin rarely trigger the same scrutiny as a hospital-based prescribing decision. That gap deserves attention.

Stewardship programs that have not explicitly addressed off-label immunomodulatory indications for macrolides are, in effect, leaving a segment of macrolide utilization unexamined.

A Practical Framework for Prescribing Decisions

For clinicians considering azithromycin in a patient with refractory CRS, several criteria help define appropriate candidacy:

Patient selection should prioritize CRSsNP. Patients with endoscopically or symptomatically confirmed CRS without nasal polyps and normal or low serum IgE represent the subgroup with the most consistent evidence of benefit. Patients with CRSwNP should exhaust guideline-concordant options — intranasal corticosteroids, saline irrigation, and specialist evaluation — before macrolide therapy is considered.

Prior treatment failure matters. Azithromycin is not a first-line intervention. Patients should have documented failure of standard therapies, including adequate trials of intranasal corticosteroids and, where indicated, sinus surgery.

Baseline cardiac and hepatic assessment is appropriate. Even at lower doses used for immunomodulation, azithromycin carries QT-prolongation risk. Clinicians should review the patient's medication list for QT-prolonging agents and consider a baseline ECG in patients with cardiac risk factors or electrolyte abnormalities.

Define duration and endpoints prospectively. Courses of 12 weeks are most commonly studied. Clinicians should document baseline symptom scores using a validated instrument such as the SNOT-22, establish a clear reassessment point, and commit to discontinuation if objective or subjective improvement is not evident.

Resistance implications warrant patient counseling. Patients should understand that while the intent of therapy is anti-inflammatory, the drug is still an antibiotic with population-level implications for resistance. This is not a reason to categorically withhold treatment, but it is a reason to use it judiciously.

Monitoring During Therapy

Beyond cardiac monitoring, clinicians prescribing extended azithromycin courses should watch for signs of hepatotoxicity, which — while uncommon — has been reported with prolonged macrolide use. Liver function testing at baseline and midpoint in longer courses is a reasonable precaution, particularly in patients with pre-existing hepatic disease or concurrent hepatotoxic medications.

Hearing changes and tinnitus, though more commonly associated with higher doses, should also prompt reassessment. Gastrointestinal tolerability is generally acceptable at low doses, but remains a reason for early discontinuation in some patients.

The Bottom Line for Clinical Practice

Azithromycin's role in chronic rhinosinusitis is neither pseudoscience nor established standard of care — it occupies the clinically uncomfortable middle ground of a biologically plausible intervention supported by moderate-quality evidence in a specific patient subset. For US clinicians managing patients with refractory CRSsNP who have exhausted first-line options, a carefully considered, time-limited course of low-dose azithromycin represents a defensible choice when supported by shared decision-making and structured monitoring.

What this indication requires — and what it too rarely receives — is the same scrutiny applied to any off-label antibiotic use: explicit patient selection criteria, a defined endpoint, and a stewardship-conscious awareness that even immunomodulatory macrolide prescribing carries resistance consequences that extend beyond the individual patient.